Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Medications development: successes and challenges.

Frank Vocci1, Walter Ling

  • 1Division of Pharmacotherapies and Medical Consequences of Drug Abuse, National Institute on Drug Abuse, National Institutes of Health, 6001 Executive Boulevard, Ste 4123, MSC 9551, Bethesda, MD 20892, USA. fv6k@nih.gov

Pharmacology & Therapeutics
|August 9, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Advancing Kratom Science and Regulation: A Comparative Framework With Cannabis.

Journal of addiction medicine·2026
Same author

Revisiting Preaddiction.

Journal of addiction medicine·2024
Same author

Psychometric properties of the Treatment Effectiveness Assessment in methamphetamine use disorder.

Journal of substance use and addiction treatment·2023
Same author

Continued Posttrial Benefits of Buprenorphine Extended Release: RECOVER Study Findings.

Journal of addiction medicine·2022
Same author

Novel rapid-acting sublingual nicotine tablet as a cigarette substitution strategy.

Psychopharmacology·2022
Same author

Moderation of buprenorphine therapy for cocaine dependence efficacy by variation of the Prodynorphin gene.

European journal of clinical pharmacology·2022
Same journal

Protein acetylation modification in tissue fibrosis: Opportunities and challenges.

Pharmacology & therapeutics·2026
Same journal

Nipocalimab and other FcRn blockers in neuromuscular disorders.

Pharmacology & therapeutics·2026
Same journal

C26:0-lysophosphatidylcholine in X-linked adrenoleukodystrophy.

Pharmacology & therapeutics·2026
Same journal

The CircRNA/miRNA axis in breast cancer: From molecular mechanisms to clinical translation.

Pharmacology & therapeutics·2026
Same journal

Glymphatic-meningeal lymphatic dysfunction in epilepsy: novel mechanistic insights and therapeutic avenues.

Pharmacology & therapeutics·2026
Same journal

The neurovascular unit under siege: Molecular mechanisms and potential drug target for cerebral edema.

Pharmacology & therapeutics·2026
See all related articles

The National Institute on Drug Abuse (NIDA) is developing medications for opiate, cocaine, and methamphetamine dependence. Research is ongoing for cannabis dependence treatments, including managing withdrawal symptoms.

Area of Science:

  • Addiction medicine
  • Neuroscience of addiction
  • Pharmacological treatments for substance use disorders

Background:

  • The National Institute on Drug Abuse (NIDA) has funded a significant medications development program.
  • Focus has been on creating treatments for opiate and cocaine dependence.

Purpose of the Study:

  • To outline the progress and future directions of NIDA's medications development program.
  • To highlight approved medications and ongoing research for various substance use disorders.

Main Methods:

  • Development and FDA approval of medications like LAAM and buprenorphine/naloxone for opiate dependence.
  • Clinical trials evaluating existing and novel medications for cocaine, methamphetamine, and cannabis dependence.
  • Investigating treatments for withdrawal symptoms and co-occurring conditions in cannabis dependence.

Related Experiment Videos

Main Results:

  • Levomethadyl acetate (LAAM), buprenorphine, and buprenorphine/naloxone are FDA-approved for opiate dependence.
  • Several medications show efficacy for cocaine use reduction, with confirmatory studies ongoing.
  • No medications have yet demonstrated efficacy for methamphetamine use reduction.
  • Initial studies for cannabis use reduction and associated symptoms are underway.

Conclusions:

  • Medications development for opiate dependence requires further research in special populations and translation of neuroscience findings.
  • Continued research is essential to identify effective treatments for cocaine, methamphetamine, and cannabis dependence.
  • NIDA's program is actively pursuing diverse pharmacological strategies to combat substance use disorders.